All patients
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children corticosteroids: no corticosteroids: yes critical disease delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression invasive ventilation kidney transplant recipients no oxygen needed non invasive oxygen obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline severe disease solid cancer solid organ transplant recipients subjects at risk
potential COVID-19 treatments in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias 14-days deathsdetailed results ConPlas-19, 2020 0.56 [0.20; 1.57]
DAWN-Plasma, 2021 0.61 [0.24; 1.55]
NCT04397757, 2021 0.47 [0.04; 5.45]
Sekine (PLACOVID), 2021 2.14 [0.70; 6.58]
0.82 [0.42 ; 1.61 ] ConPlas-19, 2020, DAWN-Plasma, 2021, NCT04397757, 2021, Sekine (PLACOVID), 2021 4 24% 1,072 moderate not evaluable death D28detailed results ACTT-2 (Kalil), 2020 0.65 [0.39; 1.09]
AlQahtani, 2020 0.47 [0.04; 5.69]
Aman, 2021 0.51 [0.27; 0.96]
ASCOT, 2021 0.60 [0.06; 5.99]
Balcells, 2020 4.22 [0.33; 53.77]
Bennett-Guerrero, 2021 0.86 [0.24; 3.11]
CAN-COVID, 2020 0.67 [0.30; 1.50]
Co-CLARITY, 2021 0.92 [0.02; 50.28]
COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41]
COLCOVID, 2021 0.88 [0.70; 1.11]
CONCOR-1, 2021 1.12 [0.86; 1.46]
ConPlas-19, 2020 0.49 [0.20; 1.19]
CONTAIN COVID-19, 2021 0.86 [0.60; 1.25]
COPLA-II trial, 2020 1.17 [0.72; 1.92]
CORIMUNO-ANA-1, 2021 0.91 [0.38; 2.19]
CORIMUNO-SARI-1 (non ICU), 2021 0.59 [0.23; 1.51]
CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80]
COV-BARRIER, 2021 0.57 [0.41; 0.79]
COV-BARRIER (critically ill), 2022 0.54 [0.31; 0.95]
COVACTA (Rosas), 2020 1.02 [0.62; 1.68]
DAWN-Plasma, 2021 0.99 [0.52; 1.88]
Declercq J (COV-AID), 2021 1.02 [0.39; 2.66]
EU-CTR2020-001375-32 (PreToVid), 0 0.59 [0.33; 1.06]
EU-CTR2020-001748-24 (ImmCoVA), 0 1.25 [0.16; 9.72]
Gaitan-Duarte (Rosuvastatin plus colchicine), 2021 0.81 [0.48; 1.36]
Horby, 2021 1.01 [0.93; 1.10]
ITAC, 2022 0.80 [0.42; 1.52]
Jamaati, 2021 1.19 [0.38; 3.72]
Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
Kirenga, 2021 1.25 [0.46; 3.39]
Lanzoni, 2021 0.14 [0.02; 0.96]
Li, 2020 0.59 [0.22; 1.59]
LIFESAVER, 2021 2.00 [0.16; 24.66]
MARIPOSA, 2021 1.43 [0.42; 4.87]
Menichetti, 2021 0.75 [0.37; 1.53]
Metcovid, 2020 0.92 [0.67; 1.28]
NCT04397757, 2021 0.15 [0.03; 0.75]
NCT04403477 (two doses), 2021 0.53 [0.14; 2.01]
NCT04412772 (ARCHITECTS), 0 0.18 [0.01; 3.72]
NCT04434717 (COVITOZ-1 single dose plus two doses), 0 0.52 [0.01; 28.31]
NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0 0.07 [0.01; 0.88]
NCT04528368, 2021 0.88 [0.02; 50.20]
NCT04577534 (COVIDSTORM), 0 0.49 [0.01; 26.18]
O’Donnell, 2021 0.47 [0.21; 1.06]
Pandit, 2021 0.95 [0.02; 50.33]
PC/COVID-19, 2021 0.63 [0.11; 3.58]
PERUCONPLASMA, 2021 0.36 [0.04; 3.13]
PlasmAr, 2020 0.93 [0.47; 1.85]
Pouladzadeh, 2021 0.31 [0.01; 10.20]
Raman, 2021 0.49 [0.02; 15.10]
RECOVER, 2021 1.09 [0.38; 3.13]
RECOVERY, 2022 0.87 [0.77; 0.98]
RECOVERY (colchicine), 2021 1.01 [0.93; 1.10]
RECOVERY (plasma), 2021 1.00 [0.93; 1.07]
RECOVERY (REGN-COV2), 2021 0.80 [0.70; 0.91]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
Rutgers, 2021 0.59 [0.33; 1.06]
Sakoulas, 2020 0.29 [0.03; 3.13]
Sekine (PLACOVID), 2021 1.38 [0.73; 2.62]
Shashi Bhushan, 2021 4.39 [0.20; 98.33]
Shi, 2020 0.53 [0.01; 27.55]
Shu, 2020 0.38 [0.02; 8.14]
Singh (TD-0903 1mg), 2021 0.40 [0.03; 6.18]
Singh (TD-0903 3mg), 2021 0.15 [0.01; 4.34]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92]
STOP-COVID (Guimarães), 2021 0.49 [0.15; 1.62]
Tabarsi, 2020 1.10 [0.45; 2.67]
Talaschian, 2021 1.56 [0.34; 7.13]
Tang X, 2020 0.98 [0.93; 1.02]
Veiga, 2021 2.70 [0.92; 7.92]
0.90 [0.85 ; 0.95 ] ACTT-2 (Kalil), 2020, AlQahtani, 2020, Aman, 2021, ASCOT, 2021, Balcells, 2020, Bennett-Guerrero, 2021, CAN-COVID, 2020, Co-CLARITY, 2021, COL-COVID (Pascual-Figal), 2021, COLCOVID, 2021, CONCOR-1, 2021, ConPlas-19, 2020, CONTAIN COVID-19, 2021, COPLA-II trial, 2020, CORIMUNO-ANA-1, 2021, CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-ICU (Group 2), 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, DAWN-Plasma, 2021, Declercq J (COV-AID), 2021, EU-CTR2020-001375-32 (PreToVid), 0, EU-CTR2020-001748-24 (ImmCoVA), 0, Gaitan-Duarte (Rosuvastatin plus colchicine), 2021, Horby, 2021, ITAC, 2022, Jamaati, 2021, Kalil (ACTT-3), 2021, Kirenga, 2021, Lanzoni, 2021, Li, 2020, LIFESAVER, 2021, MARIPOSA, 2021, Menichetti, 2021, Metcovid, 2020, NCT04397757, 2021, NCT04403477 (two doses), 2021, NCT04412772 (ARCHITECTS), 0, NCT04434717 (COVITOZ-1 single dose plus two doses), 0, NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0, NCT04528368, 2021, NCT04577534 (COVIDSTORM), 0, O’Donnell, 2021, Pandit, 2021, PC/COVID-19, 2021, PERUCONPLASMA, 2021, PlasmAr, 2020, Pouladzadeh, 2021, Raman, 2021, RECOVER, 2021, RECOVERY, 2022, RECOVERY (colchicine), 2021, RECOVERY (plasma), 2021, RECOVERY (REGN-COV2), 2021, Rosas (REMDACTA), 2021, Rutgers, 2021, Sakoulas, 2020, Sekine (PLACOVID), 2021, Shashi Bhushan, 2021, Shi, 2020, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, STOP-COVID (Guimarães), 2021, Tabarsi, 2020, Talaschian, 2021, Tang X, 2020, Veiga, 2021 70 23% 62,873 moderate critical death or transfer to ICUdetailed results BACC Bay Tocilizumab Trial, 2020 0.97 [0.50; 1.88]
Lopardo, 2021 0.65 [0.35; 1.22]
0.79 [0.50 ; 1.24 ] BACC Bay Tocilizumab Trial, 2020, Lopardo, 2021 2 0% 483 moderate not evaluable deathsdetailed results ACTIV-3/ TICO (sotrovimab), 2021 1.02 [0.48; 2.17]
ACTIV-3/TICO (tixa), 2022 0.70 [0.50; 0.97]
ACTIV-3/TICO LY-CoV555 , 2020 1.71 [0.56; 5.21]
ACTT-2 (Kalil), 2020 0.65 [0.39; 1.09]
AlQahtani, 2020 0.47 [0.04; 5.69]
Aman, 2021 0.51 [0.27; 0.96]
ASCOT, 2021 0.60 [0.06; 5.99]
BACC Bay Tocilizumab Trial, 2020 1.52 [0.41; 5.62]
Balcells, 2020 3.26 [0.62; 17.12]
Baldeon, 2022 1.85 [0.49; 6.97]
Bennett-Guerrero, 2021 0.80 [0.26; 2.45]
CAN-COVID, 2020 0.67 [0.30; 1.50]
Cao, 2020 0.15 [0.01; 3.29]
CAPE-COVID, 2020 0.45 [0.20; 1.02]
CAPSID, 2021 0.84 [0.28; 2.50]
CCAP-2, 2021 2.03 [0.61; 6.77]
Co-CLARITY, 2021 0.92 [0.02; 50.28]
CODEX (Tomazini), 2020 0.97 [0.72; 1.31]
COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41]
COLCOVID, 2021 0.88 [0.70; 1.11]
CONCOR-1, 2021 1.02 [0.77; 1.36]
ConCOVID (Gharbharan et al.), 2020 0.95 [0.20; 4.59]
CONFIDENT, 2020 0.84 [0.52; 1.37]
ConPlas-19, 2020 0.46 [0.19; 1.15]
CONTAIN COVID-19, 2021 0.86 [0.60; 1.25]
COP-COVID-19, 2021 0.96 [0.36; 2.56]
COPLA-II trial, 2020 1.17 [0.72; 1.92]
CORIMUNO-ANA-1, 2021 0.97 [0.46; 2.04]
CORIMUNO-SARI-1 (non ICU), 2021 0.59 [0.23; 1.51]
CORIMUNO-TOCI-1 (Group 1), 2020 0.92 [0.31; 2.71]
CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80]
COV-BARRIER, 2021 0.57 [0.41; 0.79]
COV-BARRIER (critically ill), 2022 0.54 [0.31; 0.95]
COVACTA (Rosas), 2020 1.16 [0.73; 1.84]
CP-COVID-19, 2021 3.20 [0.62; 16.39]
Darazam, 2021 1.21 [0.65; 2.25]
Darazam (COVIFERON Interferon beta-1a), 2021 0.31 [0.07; 1.25]
Darazam (COVIFERON Interferon beta-1b), 2021 0.52 [0.14; 1.92]
DAWN-Plasma, 2021 0.99 [0.52; 1.88]
Declercq J (COV-AID), 2021 1.02 [0.39; 2.66]
DEXA-COVID19, 2020 2.00 [0.21; 18.87]
EMPACTA, 2020 1.13 [0.54; 2.40]
EU-CTR2020-001375-32 (PreToVid), 0 0.59 [0.33; 1.06]
EU-CTR2020-001748-24 (ImmCoVA), 0 1.25 [0.16; 9.72]
Fu, 2020 1.00 [0.02; 51.66]
Gaitan-Duarte (Rosuvastatin plus colchicine), 2021 0.81 [0.48; 1.36]
GRECCO-19, 2020 0.21 [0.02; 1.97]
Holm K, 2021 0.49 [0.08; 2.89]
Horby, 2021 1.01 [0.93; 1.10]
ITAC, 2022 0.80 [0.42; 1.52]
Jamaati, 2021 1.19 [0.38; 3.72]
Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
Kirenga, 2021 1.25 [0.46; 3.39]
Lanzoni, 2021 0.11 [0.01; 0.93]
Lescure (Sarilumab 200mg), 2021 1.23 [0.49; 3.12]
Lescure (Sarilumab 400mg), 2021 0.97 [0.38; 2.50]
Li, 2020 0.59 [0.22; 1.59]
Li, 2021 1.04 [0.02; 53.73]
Libster, 2020 0.50 [0.09; 2.71]
LIFESAVER, 2021 2.00 [0.16; 24.66]
LIVE-AIR (Temesgen), 2021 0.70 [0.40; 1.21]
Lopardo, 2021 0.57 [0.24; 1.37]
Menichetti, 2021 0.75 [0.37; 1.53]
Metcovid, 2020 0.92 [0.67; 1.28]
NCT04385199, 2021 0.75 [0.15; 3.77]
NCT04397757, 2021 0.15 [0.03; 0.75]
NCT04403477 (two doses), 2021 0.53 [0.14; 2.01]
NCT04412772 (ARCHITECTS), 0 0.18 [0.01; 3.72]
NCT04434717 (COVITOZ-1 single dose plus two doses), 0 0.52 [0.01; 28.31]
NCT04442191, 2021 0.11 [0.00; 143.68]
NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0 0.07 [0.01; 0.88]
NCT04528368, 2021 0.88 [0.02; 50.20]
NCT04577534 (COVIDSTORM), 0 0.49 [0.01; 26.18]
O’Donnell, 2021 0.47 [0.21; 1.06]
Pandit, 2021 0.95 [0.02; 50.33]
PC/COVID-19, 2021 0.63 [0.11; 3.58]
PERUCONPLASMA, 2021 0.36 [0.04; 3.13]
PlasmAr, 2020 0.93 [0.47; 1.85]
Pouladzadeh, 2021 0.31 [0.01; 10.20]
Rahmani, 2020 0.29 [0.05; 1.56]
Raman, 2021 0.49 [0.02; 15.10]
Ranjbar, 2021 0.40 [0.15; 1.08]
Rasheed, 2020 0.13 [0.01; 1.09]
RCT-TCZ-COVID-19, 2021 2.24 [0.20; 25.37]
RECOVER, 2021 1.09 [0.38; 3.13]
RECOVERY, 2021 0.85 [0.76; 0.95]
RECOVERY, 2022 0.87 [0.77; 0.98]
RECOVERY (colchicine), 2021 1.01 [0.93; 1.10]
RECOVERY (plasma), 2021 1.00 [0.93; 1.07]
RECOVERY (REGN-COV2), 2021 0.80 [0.70; 0.91]
RECOVERY dexamethasone, 2020 0.83 [0.75; 0.92]
REMAP-CAP (plasma), 2021 0.96 [0.80; 1.15]
REMAP-CAP (tocilizumab), 2021 0.70 [0.51; 0.95]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
Rutgers, 2021 0.62 [0.36; 1.07]
Sakoulas, 2020 0.29 [0.03; 3.13]
Salehzadeh, 2020 1.00 [0.02; 51.41]
SAVE-MORE, 2021 0.45 [0.20; 0.99]
Sekine (PLACOVID), 2021 1.38 [0.73; 2.62]
Shashi Bhushan, 2021 4.39 [0.20; 98.33]
Shi, 2020 0.53 [0.01; 27.55]
Shu, 2020 0.38 [0.02; 8.14]
Singh (TD-0903 1mg), 2021 0.40 [0.03; 6.18]
Singh (TD-0903 3mg), 2021 0.15 [0.01; 4.34]
Soin AS (COVINTOC), 2021 0.67 [0.29; 1.55]
SOLIDARITY (interferon), 2020 1.16 [0.96; 1.40]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92]
Steroids-SARI, 2020 0.91 [0.29; 2.86]
STOP-COVID (Guimarães), 2021 0.49 [0.15; 1.62]
Synairgen SG016, 2020 0.16 [0.01; 3.31]
Tabarsi, 2020 1.10 [0.45; 2.67]
Talaschian, 2021 1.25 [0.30; 5.14]
Tang X, 2020 0.98 [0.93; 1.02]
Veiga, 2021 2.70 [0.92; 7.92]
Wang, 2020 1.00 [0.02; 52.54]
0.89 [0.85 ; 0.93 ] ACTIV-3/ TICO (sotrovimab), 2021, ACTIV-3/TICO (tixa), 2022, ACTIV-3/TICO LY-CoV555 , 2020, ACTT-2 (Kalil), 2020, AlQahtani, 2020, Aman, 2021, ASCOT, 2021, BACC Bay Tocilizumab Trial, 2020, Balcells, 2020, Baldeon, 2022, Bennett-Guerrero, 2021, CAN-COVID, 2020, Cao, 2020, CAPE-COVID, 2020, CAPSID, 2021, CCAP-2, 2021, Co-CLARITY, 2021, CODEX (Tomazini), 2020, COL-COVID (Pascual-Figal), 2021, COLCOVID, 2021, CONCOR-1, 2021, ConCOVID (Gharbharan et al.), 2020, CONFIDENT, 2020, ConPlas-19, 2020, CONTAIN COVID-19, 2021, COP-COVID-19, 2021, COPLA-II trial, 2020, CORIMUNO-ANA-1, 2021, CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-1 (Group 1), 2020, CORIMUNO-TOCI-ICU (Group 2), 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, CP-COVID-19, 2021, Darazam, 2021, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, DAWN-Plasma, 2021, Declercq J (COV-AID), 2021, DEXA-COVID19, 2020, EMPACTA, 2020, EU-CTR2020-001375-32 (PreToVid), 0, EU-CTR2020-001748-24 (ImmCoVA), 0, Fu, 2020, Gaitan-Duarte (Rosuvastatin plus colchicine), 2021, GRECCO-19, 2020, Holm K, 2021, Horby, 2021, ITAC, 2022, Jamaati, 2021, Kalil (ACTT-3), 2021, Kirenga, 2021, Lanzoni, 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Li, 2020, Li, 2021, Libster, 2020, LIFESAVER, 2021, LIVE-AIR (Temesgen), 2021, Lopardo, 2021, Menichetti, 2021, Metcovid, 2020, NCT04385199, 2021, NCT04397757, 2021, NCT04403477 (two doses), 2021, NCT04412772 (ARCHITECTS), 0, NCT04434717 (COVITOZ-1 single dose plus two doses), 0, NCT04442191, 2021, NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0, NCT04528368, 2021, NCT04577534 (COVIDSTORM), 0, O’Donnell, 2021, Pandit, 2021, PC/COVID-19, 2021, PERUCONPLASMA, 2021, PlasmAr, 2020, Pouladzadeh, 2021, Rahmani, 2020, Raman, 2021, Ranjbar, 2021, Rasheed, 2020, RCT-TCZ-COVID-19, 2021, RECOVER, 2021, RECOVERY, 2021, RECOVERY, 2022, RECOVERY (colchicine), 2021, RECOVERY (plasma), 2021, RECOVERY (REGN-COV2), 2021, RECOVERY dexamethasone, 2020, REMAP-CAP (plasma), 2021, REMAP-CAP (tocilizumab), 2021, Rosas (REMDACTA), 2021, Rutgers, 2021, Sakoulas, 2020, Salehzadeh, 2020, SAVE-MORE, 2021, Sekine (PLACOVID), 2021, Shashi Bhushan, 2021, Shi, 2020, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Soin AS (COVINTOC), 2021, SOLIDARITY (interferon), 2020, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, Steroids-SARI, 2020, STOP-COVID (Guimarães), 2021, Synairgen SG016, 2020, Tabarsi, 2020, Talaschian, 2021, Tang X, 2020, Veiga, 2021, Wang, 2020 115 22% 87,838 moderate critical deaths (time to event analysis only)detailed results ACTIV-3/ TICO (sotrovimab), 2021 1.02 [0.48; 2.17]
ACTIV-3/TICO (tixa), 2022 0.70 [0.50; 0.97]
ACTT-2 (Kalil), 2020 0.65 [0.39; 1.09]
Balcells, 2020 3.26 [0.62; 17.12]
Baldeon, 2022 1.85 [0.49; 6.97]
Bennett-Guerrero, 2021 0.80 [0.26; 2.45]
COLCOVID, 2021 0.88 [0.70; 1.11]
CONCOR-1, 2021 1.02 [0.77; 1.36]
ConPlas-19, 2020 0.46 [0.19; 1.15]
COV-BARRIER, 2021 0.57 [0.41; 0.79]
COVACTA (Rosas), 2020 1.16 [0.73; 1.84]
CP-COVID-19, 2021 3.20 [0.62; 16.39]
DAWN-Plasma, 2021 0.99 [0.52; 1.88]
Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
Lanzoni, 2021 0.11 [0.01; 0.93]
LIVE-AIR (Temesgen), 2021 0.70 [0.40; 1.21]
PlasmAr, 2020 0.93 [0.47; 1.85]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
Rutgers, 2021 0.62 [0.36; 1.07]
Talaschian, 2021 1.25 [0.30; 5.14]
0.84 [0.72 ; 0.98 ] ACTIV-3/ TICO (sotrovimab), 2021, ACTIV-3/TICO (tixa), 2022, ACTT-2 (Kalil), 2020, Balcells, 2020, Baldeon, 2022, Bennett-Guerrero, 2021, COLCOVID, 2021, CONCOR-1, 2021, ConPlas-19, 2020, COV-BARRIER, 2021, COVACTA (Rosas), 2020, CP-COVID-19, 2021, DAWN-Plasma, 2021, Kalil (ACTT-3), 2021, Lanzoni, 2021, LIVE-AIR (Temesgen), 2021, PlasmAr, 2020, Rosas (REMDACTA), 2021, Rutgers, 2021, Talaschian, 2021 20 31% 11,076 moderate low clinical deteriorationdetailed results BACC Bay Tocilizumab Trial, 2020 1.11 [0.59; 2.09]
Balcells, 2020 1.46 [0.44; 4.81]
Cao, 2020 0.11 [0.01; 2.21]
CAPSID, 2021 0.63 [0.29; 1.40]
CODEX (Tomazini), 2020 0.66 [0.43; 1.02]
COL-COVID (Pascual-Figal), 2021 0.38 [0.09; 1.58]
ConPlas-19, 2020 1.00 [0.65; 1.53]
CONTAIN COVID-19, 2021 0.94 [0.75; 1.18]
CORIMUNO-ANA-1, 2021 0.89 [0.42; 1.92]
CORIMUNO-SARI-1 (non ICU), 2021 1.01 [0.48; 2.12]
CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.26; 1.20]
COV-BARRIER, 2021 1.12 [0.58; 2.16]
EMPACTA, 2020 0.55 [0.33; 0.92]
GRECCO-19, 2020 0.11 [0.01; 1.08]
Kirenga, 2021 0.91 [0.38; 2.17]
Li, 2021 0.52 [0.02; 15.78]
Libster, 2020 0.52 [0.29; 0.94]
Ravichandran, 2021 0.02 [0.00; 0.36]
RCT-TCZ-COVID-19, 2021 1.05 [0.59; 1.86]
SAVE-MORE, 2021 0.36 [0.26; 0.50]
Shu, 2020 0.27 [0.01; 5.58]
Soin AS (COVINTOC), 2021 0.67 [0.26; 1.77]
STOP-COVID (Guimarães), 2021 0.54 [0.27; 1.07]
Synairgen SG016, 2020 0.50 [0.18; 1.38]
Tang X, 2020 1.00 [0.13; 7.45]
Wang, 2020 1.00 [0.02; 52.54]
0.70 [0.57 ; 0.86 ] BACC Bay Tocilizumab Trial, 2020, Balcells, 2020, Cao, 2020, CAPSID, 2021, CODEX (Tomazini), 2020, COL-COVID (Pascual-Figal), 2021, ConPlas-19, 2020, CONTAIN COVID-19, 2021, CORIMUNO-ANA-1, 2021, CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-1 (Group 1), 2020, COV-BARRIER, 2021, EMPACTA, 2020, GRECCO-19, 2020, Kirenga, 2021, Li, 2021, Libster, 2020, Ravichandran, 2021, RCT-TCZ-COVID-19, 2021, SAVE-MORE, 2021, Shu, 2020, Soin AS (COVINTOC), 2021, STOP-COVID (Guimarães), 2021, Synairgen SG016, 2020, Tang X, 2020, Wang, 2020 26 48% 5,000 moderate low clinical improvementdetailed results ACTIV-3/TICO (tixa), 2022 1.08 [0.97; 1.20]
ACTIV-3/TICO LY-CoV555 , 2020 0.85 [0.56; 1.29]
ACTT-2 (Kalil), 2020 1.16 [1.01; 1.33]
BACC Bay Tocilizumab Trial, 2020 1.06 [0.80; 1.41]
Balcells, 2020 0.91 [0.52; 1.60]
Bennett-Guerrero, 2021 0.75 [0.21; 2.68]
CAN-COVID, 2020 1.39 [0.76; 2.54]
Cao, 2020 1.67 [0.84; 3.33]
CAPSID, 2021 1.58 [0.71; 3.49]
ConPlas-19, 2020 0.95 [0.60; 1.52]
COV-BARRIER, 2021 1.25 [1.04; 1.50]
COV-BARRIER (critically ill), 2022 2.87 [1.12; 7.36]
COVACTA (Rosas), 2020 1.19 [0.81; 1.75]
Darazam, 2021 1.37 [0.88; 2.13]
Darazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12]
Dongsheng Wang, 2020 2.37 [0.40; 13.96]
EMPACTA, 2020 1.15 [0.90; 1.47]
ITAC, 2022 1.06 [0.77; 1.45]
Kalil (ACTT-3), 2021 0.99 [0.87; 1.13]
Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41]
Li, 2020 1.40 [0.79; 2.49]
Li, 2021 1.76 [1.10; 2.81]
Lopardo, 2021 1.61 [0.75; 3.49]
O’Donnell, 2021 1.20 [0.87; 1.65]
PlasmAr, 2020 0.81 [0.50; 1.31]
Pouladzadeh, 2021 7.31 [1.62; 32.97]
REMAP-CAP (tocilizumab), 2021 1.64 [1.25; 2.15]
Sekine (PLACOVID), 2021 0.94 [0.74; 1.19]
Shashi Bhushan, 2021 0.68 [0.21; 2.20]
Shu, 2020 10.27 [1.17; 90.18]
Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60]
Singh (TD-0903 3mg), 2021 3.00 [0.20; 45.25]
Synairgen SG016, 2020 2.32 [1.07; 5.04]
Tang X, 2020 1.04 [0.67; 1.62]
1.17 [1.08 ; 1.27 ] ACTIV-3/TICO (tixa), 2022, ACTIV-3/TICO LY-CoV555 , 2020, ACTT-2 (Kalil), 2020, BACC Bay Tocilizumab Trial, 2020, Balcells, 2020, Bennett-Guerrero, 2021, CAN-COVID, 2020, Cao, 2020, CAPSID, 2021, ConPlas-19, 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, Darazam, 2021, Darazam (COVIFERON Interferon beta-1a), 2021, Dongsheng Wang, 2020, EMPACTA, 2020, ITAC, 2022, Kalil (ACTT-3), 2021, Lescure (Sarilumab 200mg), 2021, Li, 2020, Li, 2021, Lopardo, 2021, O’Donnell, 2021, PlasmAr, 2020, Pouladzadeh, 2021, REMAP-CAP (tocilizumab), 2021, Sekine (PLACOVID), 2021, Shashi Bhushan, 2021, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Synairgen SG016, 2020, Tang X, 2020 34 37% 10,315 moderate critical clinical improvement (14-day)detailed results ACTT-2 (Kalil), 2020 1.30 [1.03; 1.64]
Cao, 2020 2.00 [0.58; 6.94]
COV-BARRIER, 2021 1.28 [1.05; 1.56]
COV-BARRIER (critically ill), 2022 1.97 [0.95; 4.09]
Kalil (ACTT-3), 2021 1.01 [0.79; 1.29]
Li, 2020 2.27 [0.90; 5.72]
Li, 2021 2.86 [1.24; 6.62]
Pandit, 2021 8.77 [0.94; 81.67]
Shashi Bhushan, 2021 0.68 [0.21; 2.20]
Shu, 2020 10.27 [1.17; 90.18]
Tang X, 2020 1.33 [0.57; 3.11]
1.40 [1.12 ; 1.74 ] ACTT-2 (Kalil), 2020, Cao, 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, Kalil (ACTT-3), 2021, Li, 2020, Li, 2021, Pandit, 2021, Shashi Bhushan, 2021, Shu, 2020, Tang X, 2020 11 45% 4,274 low critical clinical improvement (21-day)detailed results Cao, 2020 1.50 [0.22; 10.08]
1.50 [0.22 ; 10.08 ] Cao, 2020 1 0% 41 NA not evaluable clinical improvement (28-day)detailed results Bennett-Guerrero, 2021 1.02 [0.25; 4.20]
COV-BARRIER (critically ill), 2022 1.82 [0.87; 3.81]
COVACTA (Rosas), 2020 1.19 [0.81; 1.75]
Li, 2020 1.42 [0.65; 3.10]
Li, 2021 4.26 [1.10; 16.44]
O’Donnell, 2021 1.38 [0.73; 2.61]
Pouladzadeh, 2021 7.31 [1.62; 32.97]
Sekine (PLACOVID), 2021 0.94 [0.74; 1.19]
Shu, 2020 3.68 [0.18; 75.54]
Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60]
Singh (TD-0903 3mg), 2021 3.00 [0.20; 45.25]
Synairgen SG016, 2020 3.15 [1.39; 7.14]
1.59 [1.14 ; 2.21 ] Bennett-Guerrero, 2021, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, Li, 2020, Li, 2021, O’Donnell, 2021, Pouladzadeh, 2021, Sekine (PLACOVID), 2021, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Synairgen SG016, 2020 12 48% 1,420 moderate critical clinical improvement (7-day)detailed results ACTIV-3/TICO LY-CoV555 , 2020 0.85 [0.56; 1.29]
Cao, 2020 2.38 [0.38; 14.70]
ITAC, 2022 1.06 [0.77; 1.45]
Li, 2020 0.98 [0.27; 3.58]
Li, 2021 1.83 [0.41; 8.14]
Shashi Bhushan, 2021 1.91 [1.03; 3.53]
Shu, 2020 6.72 [1.50; 30.07]
1.32 [0.90 ; 1.96 ] ACTIV-3/TICO LY-CoV555 , 2020, Cao, 2020, ITAC, 2022, Li, 2020, Li, 2021, Shashi Bhushan, 2021, Shu, 2020 7 47% 1,400 moderate not evaluable clinical improvement (time to event analysis only)detailed results ACTT-2 (Kalil), 2020 1.16 [1.01; 1.33]
Balcells, 2020 0.91 [0.52; 1.60]
Bennett-Guerrero, 2021 0.75 [0.21; 2.68]
Cao, 2020 1.67 [0.84; 3.33]
ConPlas-19, 2020 0.95 [0.60; 1.52]
Darazam, 2021 1.37 [0.88; 2.13]
Darazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12]
Darazam (COVIFERON Interferon beta-1b), 2021 1.42 [0.63; 3.18]
EMPACTA, 2020 1.15 [0.90; 1.47]
Kalil (ACTT-3), 2021 0.99 [0.87; 1.13]
Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41]
Lescure (Sarilumab 400mg), 2021 1.14 [0.84; 1.54]
Li, 2020 1.40 [0.79; 2.49]
Li, 2021 1.76 [1.10; 2.81]
O’Donnell, 2021 1.20 [0.87; 1.65]
PlasmAr, 2020 1.00 [0.76; 1.32]
Rahmani, 2020 3.41 [1.33; 8.73]
Tang X, 2020 1.04 [0.67; 1.62]
1.14 [1.04 ; 1.25 ] ACTT-2 (Kalil), 2020, Balcells, 2020, Bennett-Guerrero, 2021, Cao, 2020, ConPlas-19, 2020, Darazam, 2021, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, EMPACTA, 2020, Kalil (ACTT-3), 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Li, 2020, Li, 2021, O’Donnell, 2021, PlasmAr, 2020, Rahmani, 2020, Tang X, 2020 18 22% 3,919 moderate critical death or ventilationdetailed results ACTT-2 (Kalil), 2020 0.69 [0.50; 0.95]
BACC Bay Tocilizumab Trial, 2020 0.83 [0.38; 1.81]
Balcells, 2020 0.67 [0.14; 3.26]
CAPE-COVID, 2020 0.71 [0.37; 1.35]
COLCOVID, 2021 0.83 [0.67; 1.02]
CONCOR-1, 2021 1.16 [0.94; 1.43]
ConPlas-19, 2020 0.94 [0.86; 1.02]
CORIMUNO-ANA-1, 2021 0.97 [0.62; 1.52]
CORIMUNO-SARI-1 (non ICU), 2021 1.12 [0.56; 2.22]
CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.24; 1.31]
DAWN-Plasma, 2021 1.01 [0.64; 1.59]
EMPACTA, 2020 0.56 [0.32; 0.97]
LIVE-AIR (Temesgen), 2021 0.65 [0.43; 0.98]
Menichetti, 2021 0.88 [0.59; 1.32]
NCT04310228-FAVI (Zhao), 2020 3.60 [0.13; 102.66]
RECOVERY, 2021 0.85 [0.78; 0.93]
RECOVERY, 2022 0.90 [0.81; 0.99]
RECOVERY (colchicine), 2021 1.02 [0.96; 1.09]
RECOVERY (plasma), 2021 0.99 [0.93; 1.05]
RECOVERY (REGN-COV2), 2021 0.83 [0.75; 0.92]
RECOVERY dexamethasone, 2020 0.92 [0.84; 1.01]
Rosas (REMDACTA), 2021 0.98 [0.72; 1.34]
Rutgers, 2021 0.65 [0.43; 0.99]
SOLIDARITY (interferon), 2020 1.05 [0.90; 1.23]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.66 [0.46; 0.94]
STOP-COVID (Guimarães), 2021 0.63 [0.41; 0.97]
Synairgen SG016, 2020 0.38 [0.09; 1.63]
Veiga, 2021 1.54 [0.65; 3.63]
0.90 [0.86 ; 0.96 ] ACTT-2 (Kalil), 2020, BACC Bay Tocilizumab Trial, 2020, Balcells, 2020, CAPE-COVID, 2020, COLCOVID, 2021, CONCOR-1, 2021, ConPlas-19, 2020, CORIMUNO-ANA-1, 2021, CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-1 (Group 1), 2020, DAWN-Plasma, 2021, EMPACTA, 2020, LIVE-AIR (Temesgen), 2021, Menichetti, 2021, NCT04310228-FAVI (Zhao), 2020, RECOVERY, 2021, RECOVERY, 2022, RECOVERY (colchicine), 2021, RECOVERY (plasma), 2021, RECOVERY (REGN-COV2), 2021, RECOVERY dexamethasone, 2020, Rosas (REMDACTA), 2021, Rutgers, 2021, SOLIDARITY (interferon), 2020, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, STOP-COVID (Guimarães), 2021, Synairgen SG016, 2020, Veiga, 2021 28 50% 53,835 moderate critical hospital dischargedetailed results ACTIV-3/TICO LY-CoV555 , 2020 0.97 [0.78; 1.20]
CAPE-COVID, 2020 1.67 [0.87; 3.19]
ConPlas-19, 2020 1.02 [0.82; 1.28]
DAWN-Plasma, 2021 1.06 [0.87; 1.30]
EMPACTA, 2020 1.16 [0.90; 1.49]
MARIPOSA, 2021 0.88 [0.55; 1.40]
Rahmani, 2020 3.44 [0.64; 18.49]
RECOVERY (colchicine), 2021 0.98 [0.94; 1.03]
RECOVERY (plasma), 2021 0.99 [0.92; 1.07]
RECOVERY (REGN-COV2), 2021 1.19 [1.08; 1.31]
RECOVERY dexamethasone, 2020 1.10 [1.03; 1.17]
Rosas (REMDACTA), 2021 0.97 [0.79; 1.20]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 1.48 [1.05; 2.09]
Synairgen SG016, 2020 1.63 [0.61; 4.35]
1.06 [1.00 ; 1.13 ] ACTIV-3/TICO LY-CoV555 , 2020, CAPE-COVID, 2020, ConPlas-19, 2020, DAWN-Plasma, 2021, EMPACTA, 2020, MARIPOSA, 2021, Rahmani, 2020, RECOVERY (colchicine), 2021, RECOVERY (plasma), 2021, RECOVERY (REGN-COV2), 2021, RECOVERY dexamethasone, 2020, Rosas (REMDACTA), 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, Synairgen SG016, 2020 14 57% 35,785 moderate low hospitalizationdetailed results Jagannathan, 2020 1.00 [0.14; 7.34]
1.00 [0.14 ; 7.34 ] Jagannathan, 2020 1 0% 120 NA not evaluable mechanical ventilationdetailed results ACTT-2 (Kalil), 2020 0.64 [0.44; 0.93]
AlQahtani, 2020 0.67 [0.22; 2.02]
Balcells, 2020 2.98 [0.41; 21.61]
CAPE-COVID, 2020 0.95 [0.44; 2.04]
COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41]
COPLA-II trial, 2020 0.58 [0.37; 0.92]
COVACTA (Rosas), 2020 0.67 [0.39; 1.14]
Darazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.27; 3.67]
Darazam (COVIFERON Interferon beta-1b), 2021 1.00 [0.27; 3.67]
Gaitan-Duarte (Rosuvastatin plus colchicine), 2021 0.85 [0.68; 1.06]
GRECCO-19, 2020 0.17 [0.02; 1.48]
Holm K, 2021 0.39 [0.01; 12.68]
Jamaati, 2021 1.38 [0.45; 4.20]
Li, 2021 0.52 [0.02; 15.78]
MARIPOSA, 2021 0.88 [0.37; 2.10]
Metcovid, 2020 1.19 [0.56; 2.49]
NCT04397757, 2021 0.41 [0.13; 1.35]
O’Donnell, 2021 1.50 [0.47; 4.82]
PlasmAr, 2020 0.86 [0.39; 1.93]
Rahmani, 2020 0.29 [0.05; 1.56]
Ranjbar, 2021 0.36 [0.13; 0.97]
RCT-TCZ-COVID-19, 2021 1.36 [0.39; 4.69]
RECOVERY, 2022 0.87 [0.74; 1.02]
RECOVERY (colchicine), 2021 1.04 [0.93; 1.16]
RECOVERY (plasma), 2021 0.98 [0.88; 1.09]
RECOVERY dexamethasone, 2020 0.77 [0.62; 0.95]
Rutgers, 2021 0.65 [0.35; 1.24]
Sakoulas, 2020 0.19 [0.03; 1.11]
SAVE-MORE, 2021 0.47 [0.03; 7.48]
Shu, 2020 0.59 [0.02; 14.04]
Singh (TD-0903 1mg), 2021 0.09 [0.00; 2.48]
Singh (TD-0903 3mg), 2021 0.08 [0.00; 2.07]
Soin AS (COVINTOC), 2021 1.05 [0.46; 2.38]
Tabarsi, 2020 1.49 [0.59; 3.78]
0.86 [0.78 ; 0.95 ] ACTT-2 (Kalil), 2020, AlQahtani, 2020, Balcells, 2020, CAPE-COVID, 2020, COL-COVID (Pascual-Figal), 2021, COPLA-II trial, 2020, COVACTA (Rosas), 2020, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Gaitan-Duarte (Rosuvastatin plus colchicine), 2021, GRECCO-19, 2020, Holm K, 2021, Jamaati, 2021, Li, 2021, MARIPOSA, 2021, Metcovid, 2020, NCT04397757, 2021, O’Donnell, 2021, PlasmAr, 2020, Rahmani, 2020, Ranjbar, 2021, RCT-TCZ-COVID-19, 2021, RECOVERY, 2022, RECOVERY (colchicine), 2021, RECOVERY (plasma), 2021, RECOVERY dexamethasone, 2020, Rutgers, 2021, Sakoulas, 2020, SAVE-MORE, 2021, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Soin AS (COVINTOC), 2021, Tabarsi, 2020 34 22% 40,218 moderate critical mechanical ventilation (time to event analysis only)detailed results CP-COVID-19, 2021 0.66 [0.25; 1.72]
DAWN-Plasma, 2021 1.08 [0.65; 1.80]
0.97 [0.62 ; 1.52 ] CP-COVID-19, 2021, DAWN-Plasma, 2021 2 0% 583 moderate not evaluable radiologic improvement (14-day)detailed results Cao, 2020 5.54 [1.01; 30.50]
Jamaati, 2021 4.89 [1.15; 20.79]
NCT04310228-FAVI (Zhao), 2020 0.32 [0.06; 1.63]
Rashad (CLARI vs SoC), 2021 2.87 [1.56; 5.28]
Tabarsi, 2020 2.33 [0.45; 12.00]
2.38 [1.04 ; 5.46 ] Cao, 2020, Jamaati, 2021, NCT04310228-FAVI (Zhao), 2020, Rashad (CLARI vs SoC), 2021, Tabarsi, 2020 5 50% 373 moderate not evaluable viral clearance detailed results Balcells, 2020 2.66 [0.69; 10.20]
CP-COVID-19, 2021 1.12 [0.16; 7.84]
Jagannathan, 2020 0.81 [0.56; 1.18]
Li, 2021 7.68 [0.91; 65.15]
Pandit, 2021 2.33 [0.55; 9.83]
Raman, 2021 36.42 [10.85; 122.18]
Ravichandran, 2021 1.71 [0.80; 3.64]
Salman, 2020 1.00 [0.02; 53.89]
Shashi Bhushan, 2021 2.77 [1.44; 5.32]
Tang X, 2020 1.78 [1.06; 3.00]
2.53 [1.31 ; 4.90 ] Balcells, 2020, CP-COVID-19, 2021, Jagannathan, 2020, Li, 2021, Pandit, 2021, Raman, 2021, Ravichandran, 2021, Salman, 2020, Shashi Bhushan, 2021, Tang X, 2020 10 80% 980 moderate low viral clearance (time to event analysis only)detailed results Jagannathan, 2020 0.81 [0.56; 1.18]
Li, 2021 1.74 [1.10; 2.75]
Tang X, 2020 1.78 [1.06; 3.00]
1.33 [0.77 ; 2.30 ] Jagannathan, 2020, Li, 2021, Tang X, 2020 3 77% 302 moderate not evaluable viral clearance by day 14detailed results CP-COVID-19, 2021 1.51 [0.33; 6.94]
Kirenga, 2021 0.95 [0.76; 1.19]
Li, 2021 1.74 [0.71; 4.29]
Pandit, 2021 10.23 [1.12; 93.35]
Raman, 2021 36.42 [10.85; 122.18]
Shashi Bhushan, 2021 0.00 [0.00; 0.01]
1.15 [0.15 ; 9.03 ] CP-COVID-19, 2021, Kirenga, 2021, Li, 2021, Pandit, 2021, Raman, 2021, Shashi Bhushan, 2021 6 97% 1,778 moderate not evaluable viral clearance by day 7detailed results Balcells, 2020 2.66 [0.69; 10.20]
Kirenga, 2021 0.87 [0.65; 1.16]
Li, 2021 2.20 [0.95; 5.10]
Pandit, 2021 2.33 [0.55; 9.83]
Ravichandran, 2021 1.71 [0.80; 3.64]
Salman, 2020 1.00 [0.02; 53.89]
Shashi Bhushan, 2021 2.77 [1.44; 5.32]
1.75 [1.04 ; 2.96 ] Balcells, 2020, Kirenga, 2021, Li, 2021, Pandit, 2021, Ravichandran, 2021, Salman, 2020, Shashi Bhushan, 2021 7 63% 702 moderate serious ICU admissiondetailed results COL-COVID (Pascual-Figal), 2021 0.47 [0.08; 2.69]
COVACTA (Rosas), 2020 0.48 [0.25; 0.94]
CP-COVID-19, 2021 0.82 [0.35; 1.91]
Darazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.21; 4.71]
Darazam (COVIFERON Interferon beta-1b), 2021 0.46 [0.11; 1.94]
Gaitan-Duarte (Rosuvastatin plus colchicine), 2021 0.99 [0.56; 1.75]
Libster, 2020 0.33 [0.07; 1.58]
Lopardo, 2021 0.67 [0.35; 1.28]
Rahmani, 2020 0.37 [0.14; 1.00]
Rutgers, 2021 0.96 [0.55; 1.68]
Soin AS (COVINTOC), 2021 1.33 [0.67; 2.64]
Tabarsi, 2020 0.56 [0.18; 1.74]
Tang X, 2020 1.00 [0.13; 7.45]
0.76 [0.60 ; 0.96 ] COL-COVID (Pascual-Figal), 2021, COVACTA (Rosas), 2020, CP-COVID-19, 2021, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Gaitan-Duarte (Rosuvastatin plus colchicine), 2021, Libster, 2020, Lopardo, 2021, Rahmani, 2020, Rutgers, 2021, Soin AS (COVINTOC), 2021, Tabarsi, 2020, Tang X, 2020 13 0% 1,871 moderate low recoverydetailed results ACTIV-3 (BRII-196 and BRII-198), 2021 1.08 [0.88; 1.32]
ACTIV-3/ TICO (sotrovimab), 2021 1.12 [0.91; 1.37]
ACTIV-3/TICO LY-CoV555 , 2020 1.06 [0.77; 1.46]
COV-BARRIER (critically ill), 2022 1.57 [0.77; 3.20]
Lanzoni, 2021 3.46 [1.05; 11.35]
Synairgen SG016, 2020 2.19 [1.03; 4.67]
Talaschian, 2021 0.64 [0.14; 2.92]
1.17 [0.98 ; 1.39 ] ACTIV-3 (BRII-196 and BRII-198), 2021, ACTIV-3/ TICO (sotrovimab), 2021, ACTIV-3/TICO LY-CoV555 , 2020, COV-BARRIER (critically ill), 2022, Lanzoni, 2021, Synairgen SG016, 2020, Talaschian, 2021 7 25% 1,290 low not evaluable composite safety outcome detailed results ACTIV-3/TICO LY-CoV555 , 2020 1.56 [0.78; 3.11]
1.56 [0.78 ; 3.11 ] ACTIV-3/TICO LY-CoV555 , 2020 1 0% 314 NA not evaluable related AE (TRAE)detailed results Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60]
Singh (TD-0903 3mg), 2021 0.38 [0.01; 13.93]
1.26 [0.14 ; 11.07 ] Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021 2 0% 25 moderate not evaluable related SAE (TRSAE)detailed results Wang, 2020 2.04 [0.07; 63.93]
2.04 [0.07 ; 63.93 ] Wang, 2020 1 0% 48 NA not evaluable serious adverse eventsdetailed results BACC Bay Tocilizumab Trial, 2020 1.21 [0.58; 2.53]
Balcells, 2020 4.54 [0.20; 105.23]
CAN-COVID, 2020 0.73 [0.45; 1.19]
Cao, 2020 0.11 [0.01; 2.21]
CODEX (Tomazini), 2020 0.53 [0.17; 1.62]
COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41]
CONCOR-1, 2021 1.27 [1.02; 1.58]
ConPlas-19, 2020 0.89 [0.43; 1.86]
COVACTA (Rosas), 2020 0.81 [0.54; 1.22]
Dongsheng Wang, 2020 0.91 [0.02; 47.31]
ITAC, 2022 0.98 [0.66; 1.46]
Jagannathan, 2020 1.00 [0.14; 7.34]
Lanzoni, 2021 0.10 [0.01; 0.69]
Lescure (Sarilumab 200mg), 2021 1.15 [0.62; 2.12]
Lescure (Sarilumab 400mg), 2021 1.38 [0.76; 2.51]
O’Donnell, 2021 0.64 [0.35; 1.17]
Pandit, 2021 0.95 [0.02; 50.33]
PlasmAr, 2020 1.40 [0.78; 2.51]
Raman, 2021 0.49 [0.02; 15.10]
REMAP-CAP (plasma), 2021 2.28 [1.17; 4.46]
Rosas (REMDACTA), 2021 0.83 [0.59; 1.18]
Sekine (PLACOVID), 2021 1.14 [0.88; 1.48]
Shi, 2020 1.08 [0.04; 32.96]
Soin AS (COVINTOC), 2021 0.97 [0.44; 2.13]
Talaschian, 2021 7.93 [0.37; 171.38]
Veiga, 2021 1.66 [0.60; 4.59]
1.03 [0.89 ; 1.20 ] BACC Bay Tocilizumab Trial, 2020, Balcells, 2020, CAN-COVID, 2020, Cao, 2020, CODEX (Tomazini), 2020, COL-COVID (Pascual-Figal), 2021, CONCOR-1, 2021, ConPlas-19, 2020, COVACTA (Rosas), 2020, Dongsheng Wang, 2020, ITAC, 2022, Jagannathan, 2020, Lanzoni, 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, O’Donnell, 2021, Pandit, 2021, PlasmAr, 2020, Raman, 2021, REMAP-CAP (plasma), 2021, Rosas (REMDACTA), 2021, Sekine (PLACOVID), 2021, Shi, 2020, Soin AS (COVINTOC), 2021, Talaschian, 2021, Veiga, 2021 26 23% 8,109 moderate low superinfectiondetailed results ACTT-2 (Kalil), 2020 0.50 [0.32; 0.79]
CAPE-COVID, 2020 0.81 [0.49; 1.34]
Metcovid, 2020 0.98 [0.65; 1.47]
Rahmani, 2020 0.18 [0.02; 1.59]
0.70 [0.46 ; 1.07 ] ACTT-2 (Kalil), 2020, CAPE-COVID, 2020, Metcovid, 2020, Rahmani, 2020 4 53% 1,641 low not evaluable adverse eventsdetailed results Cao, 2020 1.60 [0.38; 6.81]
COL-COVID (Pascual-Figal), 2021 1.72 [0.73; 4.08]
COVACTA (Rosas), 2020 0.87 [0.52; 1.45]
Dongsheng Wang, 2020 9.64 [2.76; 33.75]
Jagannathan, 2020 1.33 [0.63; 2.78]
Kirenga, 2021 1.13 [0.50; 2.58]
Lanzoni, 2021 0.18 [0.02; 1.95]
Lescure (Sarilumab 200mg), 2021 0.97 [0.56; 1.69]
Lescure (Sarilumab 400mg), 2021 1.31 [0.76; 2.27]
NCT04310228-FAVI (Zhao), 2020 0.60 [0.05; 6.80]
Pandit, 2021 1.68 [0.47; 5.97]
Raman, 2021 1.36 [0.56; 3.30]
Ravichandran, 2021 1.04 [0.02; 52.86]
Rosas (REMDACTA), 2021 1.32 [0.92; 1.89]
Sakoulas, 2020 1.00 [0.02; 53.46]
Sekine (PLACOVID), 2021 1.08 [0.85; 1.38]
Shi, 2020 0.88 [0.38; 2.03]
Shu, 2020 2.48 [0.05; 132.54]
Singh (TD-0903 1mg), 2021 0.45 [0.01; 16.71]
Singh (TD-0903 3mg), 2021 0.04 [0.00; 1.01]
Soin AS (COVINTOC), 2021 1.50 [0.78; 2.87]
Veiga, 2021 1.65 [0.81; 3.37]
Wang, 2020 3.57 [0.93; 13.72]
1.25 [1.04 ; 1.50 ] Cao, 2020, COL-COVID (Pascual-Figal), 2021, COVACTA (Rosas), 2020, Dongsheng Wang, 2020, Jagannathan, 2020, Kirenga, 2021, Lanzoni, 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, NCT04310228-FAVI (Zhao), 2020, Pandit, 2021, Raman, 2021, Ravichandran, 2021, Rosas (REMDACTA), 2021, Sakoulas, 2020, Sekine (PLACOVID), 2021, Shi, 2020, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Soin AS (COVINTOC), 2021, Veiga, 2021, Wang, 2020 23 18% 3,149 moderate low 0.5 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-09-26 19:49 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 95,94,90,91
- treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439
- roots T: 290